WEDI adjusts ICD-10 timeline to new compliance deadline

Luke Gale | | Health Exec | Economics
Time, Deadline - 26.64 Kb
The Workgroup for Electronic Data Interchange (WEDI) issued an updated ICD-10 implementation timeline to account for the U.S. Department of Health and Human Services’ recent decision to extend the ICD-10 compliance deadline from Oct. 1, 2013 to Oct. 1, 2014.

The timeline suggests milestones to help providers, payers and vendors plan for compliance. WEDI recognizes that different healthcare organizations and stakeholders have unique needs, but believes the timeline provides a common framework for planning. All organizations should currently be past the assessment stage and moving deep into the implementation stage, according to a Sept. 3 statement.

The Reston, Va.-based health IT coalition developed the timeline with the North Carolina Healthcare Information & Communication Alliance, a 230-organization provider consortium headquartered in Research Triangle Park, N.C.

The timeline is available on the WEDI website.

Luke Gale

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.